Publicaciones en las que colabora con Celia Prior Darbonnens (19)

2022

  1. ISR8/IRF1-AS1 Is Relevant for IFNα and NF-κB Responses

    Frontiers in Immunology, Vol. 13

2021

  1. Endogenous retroelement activation by epigenetic therapy reverses the warburg effect and elicits mitochondrial-mediated cancer cell death

    Cancer Discovery, Vol. 11, Núm. 5, pp. 1268-1285

  2. Long noncoding RNA EGOT responds to stress signals to regulate cell inflammation and growth

    Journal of Immunology, Vol. 206, Núm. 8, pp. 1932-1942

2019

  1. Identification of coding and long noncoding RNAs differentially expressed in tumors and preferentially expressed in healthy tissues

    Cancer Research, Vol. 79, Núm. 20, pp. 5167-5180

2017

  1. Strategies to design clinical studies to identify predictive biomarkers in cancer research

    Cancer Treatment Reviews, Vol. 53, pp. 79-97

2016

  1. Long noncoding RNA EGOT negatively affects the antiviral response and favors HCV replication

    EMBO Reports, Vol. 17, Núm. 7, pp. 1013-1028

2014

  1. Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma

    PLoS ONE, Vol. 9, Núm. 1

  2. Synthesis and antiproliferative activity of novel selenoester derivatives

    European Journal of Medicinal Chemistry, Vol. 73, pp. 153-166

  3. Type I interferon regulates the expression of long non-coding RNAs

    Frontiers in Immunology, Vol. 5, Núm. NOV

2012

  1. Residual dormant cancer stem-cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts

    Laboratory Investigation, Vol. 92, Núm. 7, pp. 952-966

  2. The quinoline imidoselenocarbamate EI201 blocks the AKT/mTOR pathway and targets cancer stem cells leading to a strong antitumor activity

    Current Medicinal Chemistry, Vol. 19, Núm. 18, pp. 3031-3043

2011

  1. Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: Baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity

    Annals of Oncology, Vol. 22, Núm. 12, pp. 2646-2653

  2. Synthesis and antiproliferative activity of novel symmetrical alkylthio- and alkylseleno-imidocarbamates

    European Journal of Medicinal Chemistry, Vol. 46, Núm. 1, pp. 265-274

  3. Therapeutic effect of lenalidomide in a novel xenograft mouse model of human blastic NK cell lymphoma/blastic plasmacytoid dendritic cell neoplasm

    Clinical Cancer Research, Vol. 17, Núm. 19, pp. 6163-6173

2010

  1. Use of a combination of biomarkers in serum and urine to improve detection of prostate cancer

    World Journal of Urology, Vol. 28, Núm. 6, pp. 681-686

2009

  1. Identification of TNF-α and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array

    British Journal of Cancer, Vol. 101, Núm. 11, pp. 1876-1883

  2. Synthesis and pharmacological screening of several aroyl and heteroaroyl selenylacetic acid derivatives as cytotoxic and antiproliferative agents

    Molecules, Vol. 14, Núm. 9, pp. 3313-3338

2008

  1. Phenotypic and genetic characterization of circulating tumor cells by combining immunomagnetic selection and FICTION techniques

    Journal of Histochemistry and Cytochemistry, Vol. 56, Núm. 7, pp. 667-675

2007

  1. Novel potent organoselenium compounds as cytotoxic agents in prostate cancer cells

    Bioorganic and Medicinal Chemistry Letters, Vol. 17, Núm. 24, pp. 6853-6859